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Supplemental Information
I. Datasets
We analyzed published raw datasets specified below. Please refer to associated
references for details regarding sample selection, preparation, and expression profiling.
In some cases, we analyzed subsets of patient samples reported (e.g. those with
adequate clinical followup). Actual datasets that were analyzed are provided (e.g.
Dataset A). The accompanying Microsoft Excel spreadsheet contains pages with actual
results. These pages are refered to as Web Spreadsheet (i.e. Microsoft Excel
spreadsheet) followed by a letter (e.g. Web Spreadsheet A) throughout the following
text.
a.  Global Cancer Map – 64 primary adenocarcinomas and 12 metastatic
adenocarcinomas (lung, breast, prostate, colon, ovary, and uterus) from unmatched
patients prior to any treatment. Clinical stage of primary tumors and outcome
unknown 
1. See Dataset A. This study was previously published in 2001 by
Ramaswamy et al.
b.  Lung – 62 stage I and II sporadic, primary lung adenocarcinomas with > 4 years
clinical followup after surgical resection. Clinical endpoint: Overall survival 
2. See
Dataset B. This study was previously published in 2001 by Bhattacharjee at al.2
c.  Breast – 78 stage I sporadic, primary breast adenocarcinomas with > 5 years clinical
followup after lumpectomy. Clinical endpoint: Time to metastasis 
3. See Dataset C.
This study was previously published in 2002 by Van’t Veer et al.
d.  Prostate – 21 stage I sporadic, primary prostate adenocarcinomas with > 4 years
clinical followup after radical prostatectomy. Clinical endpoint: Time to PSA relapse
after radical prostatectomy 
4. See Dataset D. This study was previously published in
2002 by Singh et al.
e.  Medulloblastoma – 60 medulloblastomas with > 5 years clinical followup after multi-
modality treatment. Clinical endpoint: Overall survival 
5. See Dataset E. This study
was previously published in 2002 by Pomeroy et al.
f.  Large B-cell Lymphoma – 58 large B-cell lymphomas with >5 years clinical followup
after combination CHOP chemotherapy. Clinical endpoint: Overall survival 
6. See
Dataset F. This study was previously published in 2002 by Shipp et al.
II. Primary versus Metastatic Adenocarcinoma Comparison
We first compared 64 primary adenocarcinomas, treated as one class, to all 12
metastatic adenocarcinomas treated as a separate class using the signal-to-noise (Sx)
statistic (Dataset A). The primary tumors were from different sites as designated in the
accompanying dataset. The 12 metastases arose from the same spectrum of sites, but
were resected from a variety of end-organs:3
Sample Site of Origin Resection Site
Met__Unknown_CUP_1 Breast Lung
Met__Unknown_CUP_16 Colon Retroperitoneum
Met__Unknown_CUP_22 Lung Adrenal
Met__Unknown_CUP_12 Lung Kidney
Met__Unknown_CUP_14 Ovary Omentum
Met__Unknown_CUP_19 Uterus Omentum
Met__Metastases_9912c062_Rb Colon Ovary
Met__Metastases_HCTN_19274 Ovary Colon
Met__Metastases_MetCaP109 Prostate Bone
Met__Metastases_MetCaP125 Prostate Bone
Met__Metastases_MetCaP128 Prostate Bone
Met__Metastases_MGH_4934 Breast Lung
Re-scaling of data
The raw expression data are Affymetrix's GeneChip software (MAS 4) “average
difference” units. Each dataset was re-scaled to account for different microarray
intensities in a given set. Each column (sample) in the dataset was multiplied by 1/slope
of a least squares linear fit of the sample versus the reference (the first sample in the
dataset). This linear fit is done using only genes that have 'Present' calls in both the
sample being re-scaled and the reference. The sample chosen as reference is a typical4
one (i.e. one with the number of "P" calls closer to the average over all samples in the
dataset).
Gene mapping
The primary and metastatic adenocarcinoma comparison was done on the Affymetrix
Hu6800 / Hu35KsubA oligonucleotide microarray platform. Our primary lung
adenocarcinoma dataset was, however, analyzed using the Affymetrix U95A
oligonucleotide microarray platform. We therefore determined the universe of genes that
are common to both microarray types (Web Spreadsheet A). Mapping was performed by
matching Affymetrix probe set names to GenBank accession numbers and then mapping
the GenBank accession numbers to UniGene clusters (build #147). All genes falling into
the same UniGene clusters from both platforms were considered “mapped” genes.
These 9376 common “mapped” genes (between the Hu6800 / Hu35KsubA and U95A
platforms) were then considered when performing downstream analysis including gene
marker selection and supervised learning (see below) to identify the gene set best able
to distinguish between primary and metastatic adenocarcinomas.
Pre-processing of data
Pre-processing of the data consisted of a thresholding step followed by a filtering step.
For the upper threshold, a ceiling of 16,000 units was chosen for all experiments
because we observe fluorescence saturation of the scanner above this level; thus,
values above this cannot be reliably measured. We also used a minimum threshold of 20
units for low expression values below this level. After thresholding, gene expression
values were subjected to a variation filter that excluded genes showing minimal variation5
across the samples being analyzed.  The variation filter tests for a fold-change and
absolute variation over samples (comparing max/min and max-min with predefined
values and excluding genes not obeying both conditions), and thus excludes genes that
vary minimally across the dataset. We used a max / min < 3 and max – min < 100 (8176
of 9376 genes passed this variation filter).
Gene marker selection
Genes correlated with a particular class distinctions (e.g. class 0 and class 1) were
identified by sorting all of the genes on the array according the signal-to-noise statistic 
7
Sx = (class 0 - class 1) / ( class 0 + class1) where  and  represent the mean and
standard deviation of expression, respectively, for each class. The colorgram depicted in
Figure 1 displays the top 128 genes differentially expressed by primary
adenocarcinomas and metastatic adenocarcinomas, ordered by their signal-to-noise
ranking. These genes are also listed in Web Spreadsheet B (also Web Spreadsheet C)
with their signal-to-noise score. An unexpected finding was that the metastasis-
associated gene expression pattern appeared to be present in some primary tumors (not
the “striped” pattern in the colorgram). This observation suggested the hypothesis that
the gene expression program of metastasis may already be present in some primary
tumors at the time of diagnosis.
III. Confirming Metastasis Gene Expression In Primary Tumors 
To test the hypothesis that a metastasis program is expressed in primary tumors, we
analyzed genes that are differentially expressed by primary and metastatic6
adenocarcinomas in an independent set of 62 stage I / II primary lung adenocarcinomas
2 (Dataset B).
Gene marker selection
We began by analyzing the expression levels in the dataset that contained the primary
and metastatic adenocarcinomas (Dataset A).  Expression levels in this dataset below
20 units were assigned a value of 20, and those exceeding 16,000 units were assigned
a value of 16,000. Genes whose expression did not vary across the dataset were
removed (i.e. if max / min < 3 or max – min < 100). Genes correlated with a particular
class distinctions (e.g. class 0 and class 1) were identified by sorting all of the genes in
the dataset according the signal-to-noise statistic 
7 Sx = (class 0 - class 1) / ( class 0
+ class1) where  and  represent the mean and standard deviation of expression,
respectively, for each class. Graded numbers of these marker genes were then used to
build a weighted-voting classifier.
Supervised learning: Prediction
We next used supervised learning to determine the best number of genes capable of
distinguishing primary and metastatic adenocarcinomas. Supervised learning was
performed using a weighted voting algorithm and evaluated using leave-one-out cross-
validation 
7. Supervised learning incorporates the knowledge of class label information to
make distinctions of interest. A training data set is used to select those features that best
make a distinction. These features are then applied to an independent test data set to
validate the ability of selected features to make that distinction. We selected a subset of7
expressed genes best able to distinguish primary from metastatic adenocarcinomas and
built a computational model using a weighted-voting algorithm that uses these selected
genes to differentiate between these two classes. 
Weighted-voting algorithm
The weighted voting algorithm 
7 makes a weighted linear combination of relevant
“marker” or “informative” genes obtained in the training set to provide a classification
scheme for new samples.  The selection of features (marker genes) is accomplished by
computing the signal-to-noise statistic Sx (described above). The class predictor is
uniquely defined by the initial set of samples and marker genes.  In addition to
computing Sx, the algorithm also finds the decision boundaries (half way) between the
class means: bx = (class0 + class1) / 2 for each gene.  To predict the class of a test
sample y, each gene x in the feature set casts a vote: Vx = Sx (gx
y - bx) and the final vote
for class 0 or 1 is sign (x Vx).
Leave-one-out cross-validation
We used leave-one-out cross-validation to determine the number of genes best capable
of distinguishing primary from metastatic adenocarcinomas. Briefly, one withholds a
sample, builds a predictor based only on the remaining samples, and predicts the class
of the withheld sample. The process is repeated for each sample, and the cumulative
error rate is calculated.8
Supervised learning using this weighted-voting leave-one-out cross-validation approach
was performed using graded numbers of top primary versus metastasis markers. The
top 128 markers (64 overexpressed in primary adenocarcinomas and 64 overexpressed
in metastatic adenocarcinomas) yielded the best primary versus metastasis prediction
using cross-validation (Web Spreadsheet D), and these markers were used in
subsequent analysis (see below). As seen, a number of primary tumors are mis-
classified at metastases.
P-values for this prediction were assigned based upon the frequency with which models
generated and tested on 1000 random permutations of the class labels performed better
than models generated using the observed class labels (Web Spreadsheet E).  After
each permutation of the class distinction, weighted voting predictors with a range of
feature numbers were used to predict the identity of the held out sample.  Statistics,
including the maximum, minimum, and mean accuracies, of the models generated from
the permuted data are shown.  By performing 1000 random permutations in this manner,
the strength of the observed association was measured against chance.  When
predicting the primary tumor versus metastases distinction, the best weighted voting
model made 15 errors out of 76 samples using 128 features (using leave-one-out cross-
validation for testing).  When limiting consideration to a 128 feature model for predicting
the tumor versus metastases distinction in the permuted samples, only 12 of the 1000
permutations of the class labels made 15 or less errors (P = 0.012).  A more
conservative estimate of the p-value for the predictor can be found when the weighted
voting predictor is allowed to use any number of features to predict the permuted class
labels.  In this case, 149 of the 1000 permutations of the class labels made 15 or less
errors (P = 0.149).  9
We then used unsupervised learning, or clustering, to examine the expression of these
top markers (derived from a comparison between primary and metastatic tumors) in an
independent set of 62 stage I / II primary lung adenocarcinomas (Dataset B). Since
these lung tumors were initially profiled on the Affymetrix U95A microarray, we had to
match the 128 Hu6800 / Hu35KsubA probe sets to corresponding probe sets on the U95
microarray (Web Spreadsheet F). This corresponded to 169 probe sets of the U95A
platform (due to redundant probe sets), which were then used in the cluster analysis
described next.
Unsupervised learning: Clustering
Unsupervised learning, or clustering, involves the aggregation of a diverse collection of
data into clusters based on different features in a data set. For example, one could
divide a group of people into clusters based on any combination of eye color, waist size,
or height. Similarly, one can gather data about the various expressed genes in a
collection of tumor samples and then cluster the samples as best as possible into groups
based on the similarity of their aggregate expression profiles. Alternatively, one could
cluster genes across all samples, to identify genes that share similar patterns of
expression in varying biologic contexts. This approach has the advantage of being
unbiased and allows for the identification of structure in a complex data set without
making any a priori assumptions. We used the Cluster and TreeView software 
8 to
perform average linkage clustering, which organizes all of the data elements into a
single tree with the highest levels of the tree representing the discovered classes. For
pre-processing, we median centered genes and arrays twice (median polished) and then
normalized genes 
8. We used a weighted centered correlation for arrays and performed
average linkage clustering.10
Hierarchical clustering in the space of these 169 top metastasis probe sets
(corresponding to the 128 genes discovered on the Hu6800/35KsubA microarray set)
identified two major clusters of primary tumors (a “primary” type and a “metastatic” type)
differentially expressing two major gene clusters (C0 and C1) (Web Spreadsheet G and
Web Spreadsheet H). A Fisher test demonstrated the highly significant correlation
between gene expression in either primaries or metastases and membership in the C0
or C1 gene cluster (and thus “primary” type or “metastatic” type primary tumors) (P =
0.002, Figure 2a) (Web Spreadsheet I).  This finding confirmed the hypothesis that the
metastasis gene expression program is indeed detectable in a subset of primary lung
tumors.
We next examined the two major clusters of primary tumors by creating a Kaplan-Meier
survival plot.
Kaplan-Meier survival analysis
Kaplan-Meier survival plots were computed using the S-Plus statistical software package
(http://www.insightful.com/products/splus/) and S-Plus 2000, Guide to Statistics Volume
2, chapter 9. The p-values for the prediction of outcome groups were computed using a
log-rank test (Mantel-Haenszel method, chapter 9 in the same reference).
If the presence of the metastasis program in a primary tumor is biologically significant,
one might expect the clinical outcome of patients with primary tumors that express this
program to be worse. Indeed, patients whose primary tumors bore the metastasis gene
expression program had significantly worse survival compared with patients whose11
tumors lacked it (P = 0.009, Figure 2b and Web Spreadsheet G), consistent with the fact
that death from lung cancer is in most cases attributable to metastasis. The metastasis
signature could be reduced to a subset of 17 genes that largely recapitulated the
observed outcome distinction (P = 0.010, Figure 2c; see below and Web Spreadsheet J).
Importantly, random selection of 17 genes failed to generate such distinctions (P =
0.004; see below and Web Spreadsheet K), indicating that this result could not have
been achieved by chance alone. Similarly, clustering the primary lung cancers in the
space of all varying genes on the microarray (9248 genes resulting from an absolute
variation filter of maxVal – minVal >100) failed to yield an outcome distinction (P = 0.8,
Figure 2d and Web Spreadsheet L). These results suggest that some primary tumors
are pre-configured to metastasize, and this propensity is detectable at the time of initial
diagnosis.
Identifying the reduced 17-gene metastasis expression signature
We reasoned that many of the top 128 metastasis genes might not be contributing
significantly to the clustering of primary lung adenocarcinoma samples, and might thus
represent “noise” in the analysis. We therefore considered the two groups (clusters) or
primary lung cancers and plotted the signal-to-noise values for each gene based on
expression in these 2 clusters (Web Spreadsheet M). We noted that 21 Affymetrix probe
sets (corresponding to 17 unique genes) were significantly correlated with the primary
lung tumor cluster distinction with a Sx > 0.4. When we clustered the primary lung
adenocarcinoma samples using this reduced metastasis gene set, and analyzed the
resulting sample clusters in a Kaplan-Meier plot, we were able to largely recapitulate the
previously observed outcome distinction (Web Spreadsheet J).12
Permutation testing to determine the statistical significance of the 17-gene metastasis
expression signature
We next asked whether this 17-gene metastasis gene expression signature yielded
outcome distinctions for primary lung adenocarcinomas that were better than what would
be observed by chance alone. We therefore selected 1000 random sets of 17-genes
from the pool of 11388 highly varying genes (Thresholded (Minimum = 2, Maximum =
16000) and filtered (Mimimum variation = 3-fold and Absolute difference = 50)) (this pre-
processing was loosened compared to that described above to allow for all genes in the
17-gene signature to pass). These gene sets were then used to perform 1000
independent clusterings of the primary lung adenocarcinomas, and each clustering was
subject to Kaplan-Meier survival analysis as described above. Notably, survival
distinctions that exceeded our observed P-value of 0.010 were seen only 4 out of 1000
permutations (P = 0.004) (Web Spreadsheet N). This observation demonstrates that the
17-gene metastasis signature is relatively unique in describing subsets of primary lung
adenocarcinoma with differential overall survival.
IV. Applying The 17-gene Metastasis Signature To Other Solid Tumor Types
To explore the generality of the metastasis signature, we applied it to other tumor types.
We first studied gene the expression profiles of 78 stage I primary breast
adenocarcinomas (Dataset C). These tumors were subjected to microarray gene
expression profiling using the 24481-gene Rosetta inkject micorarray. We mapped the
17-gene lung metastasis signature to the Rosetta platform using UniGene build #147,
which resulted in 16 successfully mapped genes (Web Spreadsheet O). We then13
performed cluster / Kaplan-Meier survival analysis as described above using these
genes (median polishing and average linkage clustering). Again, tumors bearing the
metastasis signature at diagnosis were more likely to develop distant metastases than
those lacking this signature (P = 0.024, Figure 3a and Web Spreadsheet P). A similar
result was seen in 21 prostate adenocarcinomas (using the 17 gene signature, since
both datasets were created with the U95A platform) (P = 0.022, Figure 3b and Web
Spreadsheet Q), and was even seen in a series of 58 medullobastomas (using the 21
probe sets present on the Hu6800 platform only (Web Spreadsheet R)) (P = 0.029,
Figure 3c and Web Spreadsheet S), even though these tumors are not
adenocarcinomas. These results argue for the existence of generic metastasis gene
expression programs rather than distinct mechanisms of metastasis in different tumor
types. Interestingly, however, the metastasis signature defined herein did not predict
outcome in diffuse large B-cell lymphoma (also on the Hu6800 platform; 21 probe sets)
(Figure 3d and Web Spreadsheet T), consistent with the idea that hematopoietic tumors
have specialized mechanisms for navigating the hematologic and lymphoid
compartments. Of note, the use of clustering as the analytical method allowed us to
define a metastasis signature on one microarray platform (Affymetrix HU-6800 and HU-
35k subA) and apply it to samples analyzed using different microarray designs (Rosetta
inkjet arrays and Affymetrix U95A arrays).
V. The 17-gene Metastasis Signature
The component genes of this signature are listed in Table 1 in the paper.14
The metastasis signature consisted of 8 up-regulated and 9 down-regulated genes
(Table 1 in the paper). Of note, none of the genes represent particularly striking
individual markers of metastasis (see below); rather, as demonstrated above, the
signature taken as a whole appears to contain biologically important information.  Four of
8 upregulated genes are components of the protein translation apparatus (SNRNPF,
EIF4EL3, HNRNPAB, DHPS), consistent with reports of amplification and
overexpression of translation initiation factors in invasive cancers. The Securin gene
(PTTG1), encoding an inhibitor of the enzyme Separase, is similarly overexpressed in
metastases. Separase function is required for sister chromatid separation during cell
division, and degradation of Securin at the metaphase-anaphase transition is essential
for proper chromosome segregation. A role for Securin in cancer pathogenesis is also
supported by the observation that increased Securin expression is seen in tumors with
increased vascularity and local invasion.  It is not yet clear whether these properties and
the reported ability of Securin over-expression to transform NIH 3T3 cells are related to
its role in mitosis or to some other, yet to be identified mechanism. 
The metastasis signature is also notable for the significant proportion of the signature
that appears to be derived from non-epithelial components of the tumor.  Specifically, the
Type I collagens COL1A1 and COL1A2 (whose expression is restricted to fibroblasts),
Actin 2 (ACTG2) and Calponin (CNN1) (markers of smooth muscle), MHC class II DP-
1 (HLA-DPB1) and RUNX1 (unique to hematopoietic cells) are prominent components
of the metastasis signature.  The up-regulation of collagen genes in primary tumors with
metastatic potential is consistent with the recent observations that epithelial-
mesenchymal interactions are critical determinants of tumor cell behavior.  This15
observation is also in line with reports of increased levels of Type 1 collagen in
metastatic lesions and in the serum of patients with metastatic diseases.   
Similarly, the apparent down-regulation of MHC class II expression in tumors that
metastasize likely reflects decreased numbers of infiltrating professional antigen
presenting cells (e.g. dendritic cells, macrophages) that are critical for effective anti-
tumor immune responses.  Interestingly, RUNX1 is also down-regulated in metastasis-
prone tumors and is both a putative tumor suppressor and regulates MHC class II
expression in hematopoietic cells (T.R.G. personal observation).  These observations
taken together suggest that the metastasis gene expression signature arises from both
malignant and stromal elements in primary tumors.  Of note, this major component of the
metastasis signature would have been missed had the malignant epithelial cells been
isolated (e.g. by laser capture microdissection) prior to expression profiling.
Statistical analysis of individual components of the 17-gene metastasis signature
We performed two-tailed T-tests (using S-plus) to determine the correlation between
individual genes in the metastasis signature and clinical outcome in each solid tumor
dataset to determine whether any single gene was solely capable of yielding clinical
outcome differences. The p-values for these T-tests are presented (Web Spreadsheet
T). As can be seen, few individual genes were associated with clinical outcome at a
statistically significant level (p < 0.05) in any dataset.   We also present values for our
signal-to-noise feature selection statistic (see above) for each of these genes in each
data set (Web Spreadsheet V).  This shows the direction of correlation of the individual
genes with the outcome signature in each of the datasets.16
Overlap between our Metastases signature and Rosetta’s list of 70 prognostic markers
We mapped Rosetta’s list of 70 prognostic markers 
3 for breast cancer metastasis to
probe set accession numbers on Affymetrix’s HU6800 / HU35KsubA chip set to evaluate
whether there were any genes in common with our metastases signature. Thirty-seven
of Rosetta’s list of 70 prognostic markers could be properly mapped to 53 probe sets on
Affymetrix’s HU6800 / HU35KsubA chip set (Web Spreadsheet W).  Of these 37 unique
genes, none were in either our reduced 17 gene metastases signature or in the larger
128 gene signature. It is nevertheless possible that a large number of remaining genes
that could not be successfully mapped are commonly present in the two analyses.
Outcome clustering summary
A summary of the outcome clustering in each dataset is shown in Web Spreadsheet X
and Web Spreadsheet Y.   These tables show how each sample clustered in the
datasets, provides a confusion matrix summarizing each clustering result, and provides
a summary of P-value statistics for these analyses.  Also summarized in this table are
the definitions for the clusters and observed outcome distinctions.
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